Additive effects of calcipotriol and cyclosporine A: from in vitro experiments to in vivo applications in the treatment of severe psoriasis

C R Acad Sci III. 1994 Mar;317(3):282-6.

Abstract

We report that calcipotriol (CPT) is a potent inhibitor of lymphocyte proliferation in mixed epidermal cell lymphocyte reactions. In this model, CPT and cyclosporine A (CsA) have synergistic effects. These results have led to a randomised double-blind therapeutic study protocol in patients with severe psoriasis. In these patients, topical CPT and sub-therapeutic doses of CsA (2mg/kg/d) induce disappearance of cutaneous lesions. This therapeutic association may minimize secondary side effects of both drugs.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Calcitriol / administration & dosage
  • Calcitriol / analogs & derivatives*
  • Calcitriol / pharmacology
  • Calcitriol / therapeutic use
  • Cell Division / drug effects
  • Chronic Disease
  • Cyclosporine / pharmacology
  • Cyclosporine / therapeutic use*
  • Dermatologic Agents / administration & dosage
  • Dermatologic Agents / pharmacology*
  • Dermatologic Agents / therapeutic use*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Synergism
  • Female
  • Humans
  • In Vitro Techniques
  • Lymphocyte Culture Test, Mixed
  • Lymphocytes / cytology
  • Male
  • Psoriasis / drug therapy*

Substances

  • Dermatologic Agents
  • calcipotriene
  • Cyclosporine
  • Calcitriol